{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/nappy-rash/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"3faf55b7-5b1b-55f9-87fa-6c77ae443435","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field e0ba7223-a703-4a8b-bb4d-0bc7fb30c792 --><h2>Changes</h2><!-- end field e0ba7223-a703-4a8b-bb4d-0bc7fb30c792 -->","summary":null,"htmlStringContent":"<!-- begin item d57d5f00-abe0-4faa-aa2b-91763b998c36 --><!-- begin field 06e60c0b-3510-4973-8cfb-3d7b5dd97246 --><p><strong>September 2020 </strong>— minor update. Reference to a branded barrier preparation has been removed from this topic.</p><p><strong>June to July 2018 </strong>— reviewed. A literature search was conducted in June 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring. Sections on Complications and Prognosis have been added to Background information, and the section on Differential diagnosis has been expanded. The recommendations in the Management section have been updated in line with current literature. A section on Prescribing information has been added.</p><!-- end field 06e60c0b-3510-4973-8cfb-3d7b5dd97246 --><!-- end item d57d5f00-abe0-4faa-aa2b-91763b998c36 -->","topic":{"id":"fced145b-8234-5cd6-8495-21dd435fa09e","topicId":"bf5cc007-7a69-42da-9cce-026e01ec0830","topicName":"Nappy rash","slug":"nappy-rash","lastRevised":"Last revised in September 2020","chapters":[{"id":"6bd868d7-97dc-5abb-9dd7-5bd8d9a45b42","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"285ad030-4a43-587e-b95d-111b05082bd7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"51cba348-0401-515c-b0cb-403accf300bb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3faf55b7-5b1b-55f9-87fa-6c77ae443435","slug":"changes","fullItemName":"Changes"},{"id":"5d2e0f7f-32f0-515c-acf8-f41a7793f377","slug":"update","fullItemName":"Update"}]},{"id":"6afe2031-7d04-5d34-8f93-9f76b0cee31f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"df2b7ca6-faa1-5155-b6f8-e38e875710a9","slug":"goals","fullItemName":"Goals"},{"id":"c88d8b1e-a003-5fdb-8125-60256108c8fd","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2381dd75-9264-51ce-923a-ffd47d06fb70","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9148277c-7b69-5abd-96e6-6da6cdc0692c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e337d403-433f-5884-ad90-0dc4725b9e10","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"98137183-55d3-54da-8a82-f70edd211099","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2308d842-41bc-5c6e-b14f-7a732380baae","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"25c232ac-1d36-5623-a083-670842228d71","slug":"definition","fullItemName":"Definition"},{"id":"d6bc684b-0cf9-51f4-880a-68386599241c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0baab6c3-f7e8-573b-96ee-4e51d9cb5330","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8e6a2c35-a2df-5ed9-8430-1d28fa50879e","slug":"complications","fullItemName":"Complications"},{"id":"808d9af1-4926-59a3-80ef-e810780e9314","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"34a7e7aa-63d3-5df0-9b78-2d694441515e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0f83f809-aed6-51e2-990d-c63ccf224d4e","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"36a8ef6d-dd7b-5e24-88b6-2e0d2e428522","slug":"assessment","fullItemName":"Assessment"},{"id":"da38cadb-36b7-5e94-a4d2-1ac880a9fc14","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"512f5f04-323c-5417-9d49-118aaf08ef60","fullItemName":"Management","slug":"management","subChapters":[{"id":"e22f1fdc-9a01-51a6-9519-694c4dc68f3e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"919d8121-c385-56c1-a44a-d1b60e0744d8","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"54149fa7-c48e-56d7-909c-d76fceaaa0b6","slug":"topical-imidazoles","fullItemName":"Topical imidazoles"},{"id":"3e0033c5-591d-5608-8277-0cb6706398f5","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"4a82e127-a2d6-5fae-9103-e83494a28d24","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"01431b56-1a68-53cb-9666-0bc883bec5ff","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"186815e3-961f-5ab5-b89d-b7d341d8851a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c9ab642f-9b46-54ff-a595-1e9168cbfdff","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a12c552f-6d1a-5409-a5cf-dc1efba7bb2a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d9167d23-de60-534b-b0da-c093d3a37b23","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"33ede077-9ff7-58b7-981d-d4dd371561b0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"db7928f1-0104-5ed1-8880-c59b9f060e6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"96311897-ae0a-5de9-a6a0-0cb5e181a4d3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"51cba348-0401-515c-b0cb-403accf300bb","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"24165c31-bc1a-5a64-b300-bee47cda7816","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field eb4036e4-c895-4837-9094-61c64a6eb471 --><h3>Previous changes</h3><!-- end field eb4036e4-c895-4837-9094-61c64a6eb471 -->","summary":null,"htmlStringContent":"<!-- begin item 94328b48-0db1-480a-9466-831924e39782 --><!-- begin field 2c2f7c9b-8522-4e48-a534-3a5a21ad755e --><p><strong>July 2013 </strong>— reviewed. A literature search was conducted in June 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. No major changes to recommendations have been made. There have been minor changes to the recommendations on topical treatments in the sections on treatment and treatment failure.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>January 2012 </strong>— typographical error corrected in the Treatment node. Issued in February 2012.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>August 2010 </strong>— minor update. Sulconazole 1% cream (Exelderm<sup>®</sup>) has been discontinued. The prescription has been removed. Issued in August 2010.</p><p><strong>August 2009 </strong>— minor update. Advice to apply barrier preparations thinly has been added. Issued in August 2009.</p><p><strong>March to June 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>September 2008 </strong>— minor correction to the <em>Changes </em>section. Issued September 2008.</p><p><strong>August 2008 </strong>— minor update. Nystatin cream and ointment discontinued; prescriptions removed and text amended. Issued August 2008.</p><p><strong>July to September 2006 </strong>— reviewed. Validated in December 2006 and issued in January 2007.</p><p><strong>June 2005 </strong>— minor update to drug rationales. Issued in July 2005.</p><p><strong>April 2005 </strong>— minor update. Tinaderm-M<sup>®</sup> cream (nystatin 100 000 units/g and tolnaftate 1% cream) has been discontinued. The prescription has been removed. Issued in April 2005.</p><p><strong>October 2003 </strong>— written. Validated in December 2003. Issued in February 2004.</p><!-- end field 2c2f7c9b-8522-4e48-a534-3a5a21ad755e --><!-- end item 94328b48-0db1-480a-9466-831924e39782 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}